ストックスクリーナーアプリを入手
483.07
0.38%
-1.86
アフターアワーズ：
483.07
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Fate of 23andMe genetic data still not settled amid bankruptcy fight - The Washington Post
Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial - Barron's
The New Twist In Regeneron's 23andMe Bankruptcy Buyout - Investor's Business Daily
Regeneron (REGN) Sees Modest Daily Gain on Nasdaq, Bucking Recent Downward Trend - Daily Chhattisgarh News
Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 1-Year Low on Analyst Downgrade - MarketBeat
23andMe to restart auction after former CEO wins challenge to Regeneron bid - FirstWord Pharma
UBS Group Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $560.00 - MarketBeat
UBS Maintains Neutral Rating, Lowers Price Target for REGN | REGN Stock News - GuruFocus
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock? - Yahoo Finance
Lmcg Investments LLC Buys 10,110 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
23andMe seeks second auction as ex-CEO outbids Regeneron - Seeking Alpha
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Raised by Woodstock Corp - MarketBeat
Baker Tilly Wealth Management LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Rhumbline Advisers Purchases 2,547 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Czech National Bank Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
23andMe seeks new bids after $305 million offer from its co-founder - Reuters
23andMe'S Bankruptcy Sale Sparks Bidding War - Finimize
Investor Alert: Johnson Fistel Investigates Regeneron - GlobeNewswire
DOJ Weighs in on NCAA Eligibility Lawsuit, Citing Antitrust Concerns - PYMNTS.com
Why Regeneron Is Falling And Why You Should Avoid It - Benzinga
Regeneron Licenses Weight Loss Drug and Shares Data on Muscle Preservation Medicines as Bluebird Bio Goes Private - geneonline.com
Regeneron CIO on balancing biotech innovation with regulatory demands - cio.com
Regeneron makes obesity push; Atai, Alto ink brain drug deals - BioPharma Dive
Regeneron Secures $407M Antitrust Win Over Amgen - USA Herald
Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn - PMLiVE
Wolfe Research Adjusts Price Target on Regeneron Pharmaceuticals to $800 From $925 - marketscreener.com
RBC Capital maintains neutral rating on Regeneron stock - Investing.com
Is It Time To Buy Regeneron Pharmaceuticals Stock? - Nasdaq
COPD Drug Developed by Regeneron, Sanofi Fails Key Test - MSN
Regeneron Gets $407M After Antitrust Win Over Amgen - Law360
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years - Benzinga
Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B - BioWorld MedTech
Regeneron Pharmaceuticals (NasdaqGS:REGN) Secures US$80 Million Deal For GLP-1/GIP Drug Rights - simplywall.st
Morgan Stanley Trims Regeneron (REGN) Price Target, Maintains Overweight Rating - MSN
RBC Capital maintains Regeneron Pharma stock rating at sector perform - Investing.com
Bankrupt 23andMe to be bought by pharmaceutical company Regeneron for $256 million - AOL.com
Regeneron signs licensing deal worth up to $2bn for Hansoh’s obesity drug candidate - World Pharmaceutical Frontiers
UBS maintains neutral rating on Regeneron stock amid pipeline news - Investing.com
Regeneron price target lowered to $600 from $800 at BMO Capital - Yahoo Finance
Regeneron Pharmaceuticals Stock: Is REGN Underperforming the Healthcare Sector? - MSN
ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player - insights.citeline.com
Regeneron Secures Global Rights to Hansoh’s HS-20094 Therapy Outside China - geneonline.com
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results - MSN
GuoLine Advisory Pte Ltd Buys 9,940 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Stock: Is REGN Underperforming The Healthcare Sector? - Barchart.com
Regeneron to acquire rights for Hansoh’s HS-20094 therapy - Yahoo Finance
111 Capital Invests $378,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron's weight-loss drug helps patients on Wegovy preserve muscle - MSN
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Jacobs & Co. CA - MarketBeat
Summit Global Investments Sells 7,342 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by RK Asset Management LLC - MarketBeat
Regeneron Trials Balance Quest For "Scientific Truth" With Patient Impact - Clinical Leader
GAMMA Investing LLC Acquires 814,713 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Boston Common Asset Management LLC Purchases 5,525 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN)’s Weight-Loss Drug Aids Muscle Preservation in Wegovy Users - Insider Monkey
23andMe Founder Pushes Alternative Ch. 11 Sale - Law360
Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations - insights.citeline.com
Regeneron (REGN) Downgraded at RBC Capital, Price Target Cut Sharply - Insider Monkey
Truist Securities maintains buy rating on Regeneron stock - Investing.com Australia
Hansoh licensing deal provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist - The Pharma Letter
Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target - Benzinga
Regeneron delivers reminder of Libtayo potential in non-melanoma skin cancers - The Pharma Letter
Regeneron Pharmaceuticals (REGN): Citigroup Lowers Price Target to $650 | REGN Stock News - GuruFocus
Citigroup Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Regeneron Says Phase 2 Obesity Study Interim Results Show Semaglutide Combination Preserves Lean Mass - marketscreener.com
bernstein socgen lowers regeneron pharma stock price target By Investing.com - Investing.com India
Amid Rough Waters, Regeneron Puts Nearly $2B on the Line For Chinese Obesity Drug - BioSpace
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $600.00 Price Target at BMO Capital Markets - MarketBeat
RBC Capital maintains sector perform rating on Regeneron stock - Investing.com
1.86%
大文字化:
|
ボリューム (24 時間):